These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22286821)

  • 21. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.
    Castillo N; García-García P; Rivero A; Jiménez-Sosa A; Macía M; Getino MA; Méndez ML; García-Pérez J; Navarro-González JF
    BMC Nephrol; 2012 Jul; 13():60. PubMed ID: 22799577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
    Ogawa C; Tsuchiya K; Kanda F; Maeda T
    Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.
    Lestz RM; Fivush BA; Atkinson MA
    Pediatr Nephrol; 2014 Oct; 29(10):2021-8. PubMed ID: 24794833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma ortho-tyrosine/para-tyrosine ratio with responsiveness of erythropoiesis-stimulating agent in dialyzed patients.
    Kun S; Mikolás E; Molnár GA; Sélley E; Laczy B; Csiky B; Kovács T; Wittmann I
    Redox Rep; 2014 Sep; 19(5):190-8. PubMed ID: 24693974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemoglobin variability in patients with chronic kidney disease in the Netherlands.
    van der Putten K; van der Baan FH; Schellekens H; Gaillard CA
    Int J Artif Organs; 2009 Nov; 32(11):787-93. PubMed ID: 20020410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.
    Ryta A; Chmielewski M; Debska-Slizien A; Jagodzinski P; Sikorska-Wisniewska M; Lichodziejewska-Niemierko M
    Int Urol Nephrol; 2017 May; 49(5):903-908. PubMed ID: 28058668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
    Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
    Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients.
    Yang CW; Lin MC; Shu KH; Tung KT; Tsai WC; Yang JY; Pai MF; Wu HY; Chiu YL; Peng YS; Hsu SP; Wang SH; Pan SY
    Am J Nephrol; 2023; 54(1-2):25-34. PubMed ID: 36854281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.
    Saglimbene V; Palmer SC; Craig JC; Ruospo M; Nicolucci A; Tonelli M; Johnson D; Lucisano G; Williams G; Valentini M; D'Alonzo D; Pellegrini F; Strippoli P; Salomone M; Santoro A; Maffei S; Hegbrant J; Tognoni G; Strippoli GF;
    PLoS One; 2017; 12(3):e0172735. PubMed ID: 28249030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
    Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
    Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study.
    McMahon LP; Cai MX; Baweja S; Holt SG; Kent AB; Perkovic V; Leikis MJ; Becker GJ
    BMC Nephrol; 2012 Jun; 13():40. PubMed ID: 22702540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of anemia in children receiving chronic peritoneal dialysis.
    Borzych-Duzalka D; Bilginer Y; Ha IS; Bak M; Rees L; Cano F; Munarriz RL; Chua A; Pesle S; Emre S; Urzykowska A; Quiroz L; Ruscasso JD; White C; Pape L; Ramela V; Printza N; Vogel A; Kuzmanovska D; Simkova E; Müller-Wiefel DE; Sander A; Warady BA; Schaefer F;
    J Am Soc Nephrol; 2013 Mar; 24(4):665-76. PubMed ID: 23471197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.